Eli Lilly and Company $LLY Stock Position Boosted by Amundi

Key Points

• Amundi increased its holdings in Eli Lilly and Company by 12.9% in the first quarter, owning approximately 4.95 million shares worth about $3.91 billion.
• Eli Lilly reported earnings of $6.31 per share for the latest quarter, exceeding estimates, with a revenue growth of 37.6% year-over-year.
• The company recently declared a quarterly dividend of $1.50 per share, representing an annualized dividend yield of 0.8%.

Amundi increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 12.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,953,128 shares of the company's stock after purchasing an additional 564,307 shares during the period. Eli Lilly and Company makes up approximately 1.4% of Amundi's portfolio, making the stock its 8th largest position. Amundi owned about 0.52% of Eli Lilly and Company worth $3,913,148,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in LLY. WestEnd Advisors LLC increased its holdings in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company in the first quarter valued at about $27,000. Citizens National Bank Trust Department increased its holdings in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company in the first quarter valued at about $40,000. Finally, Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $43,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. HSBC upgraded shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and increased their price target for the company from $675.00 to $700.00 in a research report on Wednesday, August 27th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Guggenheim lowered their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research report on Wednesday, August 13th. Finally, Daiwa America lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus target price of $950.17.

Insider Buying and Selling

In related news, Director Gabrielle Sulzberger purchased 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 over the last 90 days. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Trading Down 2.2%

NYSE LLY traded down $16.56 during mid-day trading on Friday, reaching $726.35. 3,953,474 shares of the stock were exchanged, compared to its average volume of 5,282,453. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $942.35. The business's fifty day simple moving average is $743.84 and its 200 day simple moving average is $781.81. The stock has a market capitalization of $687.46 billion, a PE ratio of 47.47, a PEG ratio of 1.03 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the business earned $3.92 earnings per share. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.